What Divergence does

Divergence is a privately held research and development company headquartered in St. Louis, Missouri, founded in 1999. According to its firmographic profile, the company is dedicated to the discovery of strategies for the control of parasites and other pests, placing it in the agricultural biotechnology and animal/plant health R&D sector. Its stated product focus is on developing novel parasite and pest control approaches, which historically has spanned agricultural, veterinary, and potentially human health applications.

Between 2001 and 2009, Divergence raised approximately $20.6 million in aggregate across at least six discrete funding events, including venture rounds (with participation from Ag Fund, Cultivian Ventures, Prolog Ventures, and Sandbox Industries) and non-dilutive grant funding from the National Science Foundation. The company's leadership consists of co-founder Angharad Thomas and Vice President of Discovery Research Deryck Jeremy Williams, Ph.D., indicating a research-led operating model centered on scientific discovery rather than commercial sales scale at the time of last disclosed activity.

Material data caveat: The firmographics record lists "10000+" employees, which is fundamentally inconsistent with the disclosed funding scale (~$20M total raised over an eight-year window) and with the operating profile implied by a small St. Louis R&D operation. This figure likely reflects a data-merge artifact and should be treated with caution. No revenue, pricing, customer logos, or post-2009 operating updates are disclosed in the input, so commercial traction cannot be verified.

Name

Divergence

Legal name

Bayer AG

Website

https://divergence.com

Company type

Public

Founded year

1863

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Divergence is a St. Louis-based, privately held R&D company founded in 1999 that develops strategies for controlling parasites and other pests, operating in the agricultural biotechnology space.

Ownership category

akta.pro rank

Product category

Agricultural Biotechnology

akta.pro primary industry

Beneficial Insects (Predators & Parasitoids) (AFABAEAH)

Keywords

• Pest control research
• Parasite control strategies
• Agricultural biotechnology
• Crop protection R&D
• Nematicide discovery

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Pharmaceuticals: Prescription pharmaceuticals across cardiology, oncology, hematology, ophthalmology, chronic kidney disease, and hormonal/reproductive health. Includes both in-market products and pipeline candidates in clinical development.
2. Crop Science/Agriculture: Agricultural products including crop protection (herbicides, fungicides, insecticides), seeds and traits (including GMO biotechnology and genome editing), agriculture biologicals, and digital farming solutions for farmers worldwide.
3. Consumer Health/Personal Health: Over-the-counter (OTC) consumer health products including analgesics, allergy relief, digestive health, cough and cold, skin health, hair health, vitamins, and nutritional supplements sold through retail channels.
4. Radiology/Diagnostic Imaging: Medical imaging equipment and contrast agents for computed tomography (CT), magnetic resonance tomography (MRI), angiography, and PET imaging systems sold to healthcare facilities.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Core offering

Divergence is a research and development company focused on discovering new strategies and technologies for the control of parasites and other pests in agricultural settings. The company's work centers on agricultural biotechnology, developing novel approaches to parasitic nematode and crop pest management through targeted R&D programs.

Product overview

Bayer is a global enterprise with core competencies in health care and agriculture. The company operates as a multi-divisional organization with three main pillars: Pharmaceuticals (innovative solutions for preventing, alleviating and treating diseases including cardiology, oncology, hematology, and eye conditions), Consumer Health (personal health products including OTC medicines, vitamins, and health supplements), and Crop Science (agricultural solutions including crop protection chemicals, seeds and traits, digital farming, and biologicals). The Pharmaceuticals division leverages advanced technology platforms including AI, chemoproteomics, PROTACs, RNA-targeting small molecules, and cell and gene therapy. The Agriculture division encompasses regenerative agriculture solutions, digital farming technologies, and biotechnology programs including GMO and genome editing.

Differentiator

Problem solved

Functional benefit

Brands

• Bayer Crop Science: Agricultural division offering crop protection products, seeds, digital farming solutions, and biotechnology.
• Bayer Pharmaceuticals
• Bayer Consumer Health
• Bayer Environmental Science
• Bayer Life Sciences

Products and services

• Parasite and Pest Control R&D Services Research and development services focused on discovering novel strategies and chemistries for the control of parasites (including plant-parasitic nematodes) and other agricultural pests, delivered to agricultural input companies.

Quantifiable outcome

• Commitment to reducing agriculture's environmental impact through regenerative agriculture and carbon reduction programs
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature14 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Perfuse TherapeuticscoreStrategic or Co-development Partner · 17 June 2026Bayer completed acquisition of Perfuse Therapeutics, a strategic transaction to strengthen Bayer's pharmaceutical pipeline and capabilities in a specific therapeutic area (date: June 2026).
• The Challenge InitiativecoreStrategic or Co-development PartnerPartnership to improve access to family planning services in urban areas of developing countries. Bayer contributes to scaling up contraceptive access and reproductive health programs through this initiative targeting underserved populations.
• CoverCressminorStrategic or Co-development PartnerStrategic partnership in Carbon Ventures program for developing cover crops that can be converted into renewable fuel feedstock, supporting sustainable agriculture and carbon reduction goals.
• Global LifeHub NetworkcoreStrategic or Co-development PartnerOpen innovation network connecting Bayer with academic institutions, research organizations, and technology partners globally to accelerate innovation in life sciences through collaborations and partnerships.
• Food Chain PartnershipminorStrategic or Co-development PartnerAgricultural sustainability initiative connecting Bayer with food chain partners including processors, traders, and retailers to promote sustainable sourcing and regenerative agriculture practices.
• Bayer ForwardFarmingminorStrategic or Co-development PartnerInitiative showcasing regenerative agriculture practices on partner farms, demonstrating how advanced technologies can improve sustainability while maintaining agricultural productivity.

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Market position

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries5 records

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Divergence